Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Ray, Gani"'
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 16, Iss 9, Pp 2238-2244 (2020)
Influenza is a viral respiratory disease that causes significant clinical and economic burden globally. Quadrivalent influenza vaccine (QIV) is frequently used to protect people who have a high-risk of developing influenza complications due to comorb
Externí odkaz:
https://doaj.org/article/bf2411faa6ef44e3a4e3d024e2e60e8f
Autor:
Ritika Kapoor, Baudouin Standaert, Edmund J. Pezalla, Nadia Demarteau, Kelly Sutton, Eszter Tichy, George Bungey, Sofie Arnetorp, Klas Bergenheim, Duncan Darroch-Thompson, Wilhelmine Meeraus, Lucas M. Okumura, Renata Tiene de Carvalho Yokota, Ray Gani, Terry Nolan
Publikováno v:
Vaccines, Vol 11, Iss 2, p 377 (2023)
Healthcare decision-makers face difficult decisions regarding COVID-19 booster selection given limited budgets and the need to maximize healthcare gain. A constrained optimization (CO) model was developed to identify booster allocation strategies tha
Externí odkaz:
https://doaj.org/article/ec4a5dd6bae248789ad2961f7e24c9b7
Autor:
Anna Fochesato, Sara Sottile, Andrea Pugliese, Sergio Márquez-Peláez, Hector Toro-Diaz, Ray Gani, Piedad Alvarez, Jesús Ruiz-Aragón
Publikováno v:
Vaccines, Vol 10, Iss 8, p 1360 (2022)
Standard-dose quadrivalent influenza vaccines (QIV) are designed to provide protection against all four influenza strains. Adjuvanted QIV (aQIV), indicated for individuals aged 65+ years, combines MF59® adjuvant (an oil-in-water emulsion of squalene
Externí odkaz:
https://doaj.org/article/6d83a14be09648cba151b66c9c9f0861
Publikováno v:
Vaccines, Vol 10, Iss 2, p 176 (2022)
Influenza is a contagious respiratory disease that causes severe illness and death, particularly in elderly populations. Two enhanced formulations of quadrivalent influenza vaccine (QIV) are available in Spain. Adjuvanted QIV (aQIV) is available for
Externí odkaz:
https://doaj.org/article/5c627bb2c85944d1a6ca9a503cc76850
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 3, Pp 696-697 (2021)
Externí odkaz:
https://doaj.org/article/0db4447727ee4adaa63d197b4b386a60
Autor:
Chiara Azzari, Elliott O'Brien, Ray Gani, Chiara Alimenti, Lara J. Wolfson, Vincent J. Daniels, Vincenzo Baldo, S. Giuffrida
Publikováno v:
ClinicoEconomics and Outcomes Research. 12:273-283
Background In 2017, varicella vaccination became mandatory for all children in Italy, based on a two-dose schedule administered at 12-15 months of age and 5 to 6 years of age. Varicella vaccines are available in different formulations (as a single va
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26078231f55cbbf4fb7dce2409463e54
https://doi.org/10.2147/ceor.s229685
https://doi.org/10.2147/ceor.s229685
Publikováno v:
Hum Vaccin Immunother
Influenza is a viral respiratory disease that causes significant clinical and economic burden globally. Quadrivalent influenza vaccine (QIV) is frequently used to protect people who have a high-risk of developing influenza complications due to comorb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff25d4a086f93ae6b50f85755327f089
https://doi.org/10.1080/21645515.2020.1712935
https://doi.org/10.1080/21645515.2020.1712935
Autor:
Ray Gani, Salome Samant, Ulrich Heininger, Manjiri Pawaskar, Patrik Guggisberg, Florian Lienert, Elliott O'Brien, M. Pillsbury
Publikováno v:
The Pediatric infectious disease journal. 40(6)
Background Varicella, caused by the varicella-zoster virus, is a highly contagious infectious disease with substantial health and economic burden to society. Universal varicella vaccination (UVV) is not yet recommended by the Swiss National Immunizat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::979a9fb89b5f4bb65aa0f3e24922c709
https://pubmed.ncbi.nlm.nih.gov/33872276
https://pubmed.ncbi.nlm.nih.gov/33872276
Publikováno v:
Human Vaccines & Immunotherapeutics. 17:696-697
Dear Dr. Ellis, Thank you for the opportunity to address the concerns outlined in the letter from Alvarez et al. in response to our study “Estimated Cost-effectiveness and Burden of Disease Associa...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bfd52b98ed5b5c1cf0ba1a15ef9fca65
https://doi.org/10.1080/21645515.2020.1813485
https://doi.org/10.1080/21645515.2020.1813485
Autor:
Huan, Huang, Kelly F, Bell, Ray, Gani, Cathy W, Tugwell, James M, Eudicone, Michelle R, Krukas-Hampel
Publikováno v:
The American journal of managed care. 24
The efficacy of dapagliflozin as add-on therapy to metformin has been assessed in randomized trials. However, its effectiveness has not been assessed in a US real-world setting.Electronic medical record (EMR) data were used to compare clinical outcom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dc762a4d0572e701a6b5a740fea6c349
https://pubmed.ncbi.nlm.nih.gov/29693359
https://pubmed.ncbi.nlm.nih.gov/29693359